Janez A
Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Zaloska 7, SI-1000 Ljubljana, Slovenia.
J Int Med Res. 2012;40(4):1546-51. doi: 10.1177/147323001204000434.
To evaluate the treatment indications, effectiveness and adverse events of continuous subcutaneous insulin infusion (CSII) in adults with type 1 diabetes mellitus using data from a registry at the University Medical Centre Ljubljana, Ljubljana, Slovenia.
The registry included patients with type 1 diabetes who had converted from multiple daily injection (MDI) to CSII. Patients with complete data sets covering a period of ≥3 years were included in the study (n=184). Complications, glycaemic control and insulin dose during CSII were compared with data obtained during MDI.
CSII resulted in significant reductions in glycosyated haemoglobin level and total daily insulin dose. The mean number of severe hypoglycaemic episodes during CSII was 0.17 per patient per year.
Treatment of adults with type 1 diabetes mellitus by CSII can improve glycaemic control and reduce insulin requirements compared with MDI, however patient selection, education and continuous care are important parts of this therapy.
利用斯洛文尼亚卢布尔雅那大学医学中心登记处的数据，评估持续皮下胰岛素输注（CSII）在1型糖尿病成年患者中的治疗适应证、有效性及不良事件。
该登记处纳入了从多次皮下注射（MDI）转换为CSII的1型糖尿病患者。研究纳入了数据集完整且病程≥3年的患者（n = 184）。将CSII期间的并发症、血糖控制及胰岛素剂量与MDI期间获得的数据进行比较。
CSII使糖化血红蛋白水平及每日胰岛素总剂量显著降低。CSII期间严重低血糖发作的平均次数为每位患者每年0.17次。
与MDI相比，CSII治疗1型糖尿病成年患者可改善血糖控制并减少胰岛素需求，然而患者选择、教育及持续护理是该治疗的重要组成部分。
